This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
ver-expression of the HER2/neu receptor occurs in 15 to 30 percent of breast tumors and is linked to poorer prognosis. Currently
HER2/neu expression status determines whether patient will receive trastuzumab- based treatment. In clinical practice, over-
expression of HER2/neu is identified using IHC or FISH, both of which are invasive approaches requiring tissue samples. Serum
assays for HER2/neu receptor have been reported but the use is very limited due to serum interference factors (e.g. human anti-animal
antibodies) that lead to false test results and inconsistency with tissue Her2 status. We have developed an ELISA based approach
implementing an MBB buffer to eliminate false results and to obtain more accurate assessment of HER2/neu levels. Using this refined
assay we retroactively measured HER2/neu levels from 56 patients. Pre-treatment (e.g. surgery, radiation, or chemotherapy) samples
were available from 12 patients, of which 6 patients were tissue HER2/neu positive and the other six were negative. All the HER2/
neu positive samples had higher serum levels than negative ones (p < 0.05). We observed a decrease in serum HER-2/neu values after
surgery in two out of 5 patients. In 5 patients experienced recurrence or metastasis, HER2/neu level significantly increased from the
treatment-established baseline, accompanying recurrence and before metastasis. Our results indicate that we can monitor HER2 ECD
as a biomarker over the course of disease progression and treatment.
Hongtao Zhang has been a Research Assistant Professor in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania
Perelman, School of Medicine since 2007. He graduated from University of Pennsylvania in 1999 with a Ph.D. degree in Pharmacology. Currently he
focuses on the ErbB receptor- targeted therapies using antibodies, antibody-like proteins, or small molecules. He is also devoted to the identification
of serum biomarkers that can help the diagnosis and provide therapeutic guidance for breast cancer and melanoma. He has published more than 50
papers and serves as an editorial board member for several journals.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals